<DOC>
	<DOCNO>NCT00551213</DOCNO>
	<brief_summary>The purpose study determine activity two dos robatumumab ( SCH 717454 , MK-7454 ) participant relapse recurrent colorectal cancer . The primary study hypothesis decrease Positron Emission Tomography ( PET ) -assessed tumor glucose metabolism ( i.e. , fluorodeoxyglucose [ FDG ] standardize uptake value [ SUV ] ) follow administration 10 mg/kg robatumumab exceed follow administration 0.3 mg/kg robatumumab participant relapse recurrent colorectal cancer progress first-line chemotherapy . Investigator choices standard chemotherapy : irinotecan single agent +/- cetuximab OR capecitabine single agent , OR FOLFOX ( leucovorin calcium [ folinic acid ] [ FOL ] + fluorouracil [ F ] + oxaliplatin [ OX ] ) OR CAPEO ( capecitabine [ CAPE ] Xeloda® [ XEL ] + oxaliplatin [ OX ] ) OR FOLFIRI ( leucovorin calcium [ folinic acid ] [ FOL ] + fluorouracil [ F ] + irinotecan [ IRI ] ) +/- cetuximab OR cetuximab single agent .</brief_summary>
	<brief_title>A Study Determine Activity Robatumumab ( SCH 717454 , MK-7454 ) Participants With Relapsed Recurrent Colorectal Cancer ( P04721 , MK-7454-003 )</brief_title>
	<detailed_description>Standard chemotherapy use positive validation arm . Randomization perform could bias selection participant enrollment fixed-sequence arm . Once three chemotherapy-treated participant demonstrate decrease FDG-PET SUV target lesion ( i.e. , &gt; 20 % decrease SUVmax define target lesion ) PET/computed tomography ( CT ) scan perform follow Cycle 1 Period 1 treatment , conclude positive validation arm accomplish purpose , subsequent participant enrol study assign treatment robatumumab Period 1 . There intention compare data either period across participant receive chemotherapy receive robatumumab .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Older 18 year age , race , gender ; Diagnosis histologically confirm relapsed recurrent colorectal carcinoma progress least firstline therapy ; Must compute tomography ( CT ) magnetic resonance imaging ( MRI ) scan perform point immediate prior treatment observation order determine tumor growth rate ; Must measurable disease CT MRI study , perform Screening ; Must Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; =2 minimum life expectancy ≥4 month ; Must adequate organ function within 3 week prior treatment assignment History another malignancy ; Known treat untreated leptomeningeal metastasis , metastatic central nervous system lesion ; Surgery within 3 week ; Radiation therapy within 6 week ; A history uncontrolled diabetes mellitus , define hemoglobin A1C &gt; 7.5 % participant know diabetes mellitus ; A recent myocardial infarction ( within past year ) ; participant time Screening present unstable uncontrolled angina , New York Heart Association Class III IV congestive heart failure , uncontrolled hypertension , clinically significant cardiac dysrhythmia clinically significant electrocardiogram abnormality ; An active infection ; Has clinically significant hepatitis Screening , hepatitis C antibody positive , hepatitis B surface antigen positive , human immunodeficiency virus ( HIV ) seropositive .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>anti-IGF-1R</keyword>
</DOC>